ACU Q2 2026 Earnings: MyMedic Acquisition Drives EPS Beat and Revenue Surge

• Acme United reported Q2 2026 EPS of $1.22, beating estimates by 50.62%, alongside a 16% revenue surge to $62.7 million.
• The outperformance was primarily driven by the MyMedic acquisition, which supported 8% organic growth and expanded gross margins to 42.6%.
• Management expects continued margin recovery as lower-cost inventory replaces higher-tariff stock, with strong Q4 profitability anticipated.
• Key risks include elevated SG&A expenses at 32% of sales and uneven geographic performance, particularly in Canada.

Acme United Corporation (ACU) delivered robust second-quarter 2026 financial results, posting earnings per share (EPS) of $1.22 against analyst estimates of $0.81 . This represents a significant 50.62% surprise, highlighting the company's ability to exceed market expectations . Revenue reached $62.7 million, exceeding forecasts of $58.1 million by nearly 8% . The stock responded positively to these figures, surging approximately 11.92% to approach its 52-week high of $51.88 .

The primary driver of this outperformance was the acquisition of MyMedic . Sales growth of 16% year-over-year was bolstered by this acquisition, while organic growth stood at a solid 8% excluding the new unit . Gross margins expanded significantly to 42.6% from 41.0% in the prior year period . This expansion indicates effective cost management and a favorable product mix .

How Is Acme United Mitigating Tariff Pressures?

CEO Johnsen provided forward-looking commentary, expressing confidence in continued margin recovery . He attributed this outlook to easing tariff pressures and a strategic inventory transition . Lower-cost stock is replacing higher-tariff inventory throughout the year . This process is expected to conclude by year-end, supporting further margin improvements .

The company is actively integrating MyMedic, aiming to expand its distribution beyond direct-to-consumer channels . The strategic focus is shifting toward mass retail expansion . This move is anticipated to drive strong profitability in the fourth quarter . Seasonal demand is expected to support this growth trajectory .

What Are the Key Risks and Headwinds?

Investors should monitor key risks, as Selling, General, and Administrative (SG&A) expenses remain elevated . SG&A costs currently stand at 32% of sales, which could pressure net income if not managed efficiently . Other headwinds include ongoing tariff and freight costs . Potential currency fluctuations and uneven geographic performance add to the uncertainty .

Geographic performance is uneven, with Canada currently lagging other regions . Despite these challenges, the strong earnings beat and margin improvement suggest positive near-term momentum . Management anticipates strong profitability in Q4 due to seasonal demand patterns . The integration of MyMedic remains a critical factor in sustaining this growth .

The divergence between top-line growth and bottom-line profitability has been noted . While sales are strong, elevated SG&A expenses have impacted net income . The company is actively managing tariff impacts through inventory transitions . Johnsen expects continued margin recovery as lower-cost inventory replaces higher-tariff stock .

Acme United's performance in Q2 2026 demonstrates the impact of strategic acquisitions on financial metrics . The MyMedic acquisition has been instrumental in driving both revenue and margin growth . Management's focus on cost management and tariff mitigation is crucial for sustained profitability . Investors will closely watch the integration progress and expense management in upcoming quarters .

The stock's reaction to the earnings release indicates market confidence in the company's strategy . The surge to near 52-week highs reflects positive sentiment . However, the elevated SG&A ratio remains a point of concern . Effective management of these costs will be vital for maintaining the current growth trajectory .

Acme United's ability to navigate tariff pressures and integrate new acquisitions successfully positions it well . The expansion of gross margins to 42.6% is a positive indicator . The strategic shift towards mass retail for MyMedic could unlock further value . Continued monitoring of geographic performance and cost structures is recommended .